Update (4:15 p.m.): Updated with Friday market close information and one-year low price.
NEW YORK (TheStreet) -- Cytokinetics (CYTK) plummeted more than 64% to a one-year low of $4.57 on Friday after the biotechnology company announced its experimental treatment for Lou Gehrig's disease failed to meet its primary goal in a mid-stage trial.
The study measured the efficacy of one of the San Francisco-based company's main experimental drugs, tirasemtiv, on amyotrophic lateral sclerosis, or ALS. The study tested the drug against a placebo in 711 patients.
The stock closed at $4.59, down 64.67% or $8.40 from its previous close of $12.99, at the close of trading on Friday. The stock continued to fall 2.4% to $4.48 in after-market activity. More than 17 million shares changed hands on Friday, well above the average volume of 1,054,580.Must Read: Warren Buffett's 10 Favorite Growth Stocks SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more. STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV